Medical Doctor Program year 2019 Source: CMS Open Payments, 2026 publication

Kevin Easley

Gynecologic Oncology St Louis, MO Medical Doctor

NPI 1154385417 CMS profile 324041

12855 North Forty Dr, Suite 200, St Louis, MO 63141

Open in the dashboard

General payments

$1,326

58 records reported · program year 2019

Research payments

$0

Paid to them · None reported · program year 2019

Ownership & investment interest

$0

None reported

Through program year 2019, Kevin Easley of St Louis, MO is reported in the CMS Open Payments database as having received $1,326 across 58 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 46th percentile of Gynecologic Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2019 General $1,326 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Easley
  • Gynecologic Oncology median
  • Middle half of Gynecologic Oncology
  • National median

In program year 2025, general payments to Kevin Easley were reported at $0. Among 1,179 Gynecologic Oncology profiles paid that year, the median was $305 and the middle half received between $111 and $1,499.

Show as a table
Year Kevin Easley Gynecologic Oncology median Middle half National median
2019 $1,326 $287 $113–$1,548 $163
2020 $0 $223 $59–$2,164 $114
2021 $0 $193 $68–$1,139 $132
2022 $0 $252 $90–$1,151 $149
2023 $0 $281 $102–$1,419 $160
2024 $0 $308 $108–$1,502 $164
2025 $0 $305 $111–$1,499 $169

Breakdown

Who paid General payments · program year 2019
  1. TESARO, Inc. $286 9 payments
  2. Merck Sharp & Dohme Corporation $243 10 payments
  3. AstraZeneca Pharmaceuticals LP $151 8 payments
  4. Intuitive Surgical, Inc. $87 2 payments
  5. Clovis Oncology, Inc. $86 8 payments
  6. Daiichi Sankyo Inc. $86 4 payments
  7. Ethicon US, LLC $83 2 payments
  8. Kyowa Kirin, Inc. $58 3 payments
  9. TerSera Therapeutics LLC $48 2 payments
  10. Mylan Institutional Inc. $46 2 payments
  11. Other $152 8 payments

Every payment, record by record

What the payments were for General payments · program year 2019
  1. Food and Beverage $1,312 56 payments
  2. Education $14 2 payments
Products named General payments · program year 2019
  1. ZEJULA $286 9 payments
  2. KEYTRUDA $243 10 payments
  3. LYNPARZA Oncology $151 8 payments
  4. LYNPARZA Oncology $97 6 payments
  5. Da Vinci Surgical System $87 2 payments
  6. Rubraca $86 8 payments
  7. INJECTAFER $86 4 payments
  8. SANCUSO $58 3 payments
  9. ENSEAL Product Family $49 1 payment
  10. ZOLADEX $48 2 payments
  11. Other $407 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

58 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecologic Oncology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2019

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record